Achillion (ACHN) Higher on Further HCV Development, Inhibitex Buyout; Up ~10%

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. MRNA
3. EL
4. MRK
5. BILL

6. RARE
7. LOW
8. DE
9. ADI
10. COTY

Price: $0.79 --0%

Overall Analyst Rating:
SELL (= Flat)

Achillion Pharmaceuticals (Nasdaq: ACHN), is moving higher on a few news bits today:

First it is planning further exploration of ACH-1625 in combination with other oral antiviral agents for the treatment of all HCV genotypes and continues to evaluate ACH-2684 in a Phase 1 clinical trial; and
It is reacting to the takeover of Inhibitex (Nasdaq: INHX) by Bristol-Myers Squibb (NYSE: BMY), for about a 163 percent premium.Shares are up about 10.2 percent Monday.

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!